Duobrii

DRUG3 trials

Sponsors

Bausch Health Americas Inc., Psoriasis Treatment Center of Central New Jersey, Icahn School of Medicine at Mount Sinai

Conditions

AKNAcne Keloidalis NuchaePlaque PsoriasisPsoriasis

Phase 2

A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion in Pediatric Subjects with Moderate to Severe Plaque Psoriasis

CompletedCTIS2024-520057-20-00

Bausch Health Americas Inc.Plaque Psoriasis

Start: 2021-03-09End: 2025-11-05Target: 26Updated: 2025-01-28

Phase 3

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

TerminatedNCT05608499

Icahn School of Medicine at Mount SinaiAcne Keloidalis Nuchae, AKN

Start: 2022-10-26End: 2024-04-15Updated: 2025-11-04

Phase 4

Duobrii in Combination With Biologics

RecruitingNCT04119102

Psoriasis Treatment Center of Central New JerseyPsoriasis

Start: 2019-10-14End: 2020-09-01Target: 25Updated: 2020-04-30